Top Markets
Coin of the day
Acorda Therapeutics, Inc. Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.

ACOR
Rank in Stocks #39255
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Share Price
$0.879
Last synced: 2024-05-07
Market Cap
$582.38K
Change (1 day)
9.88%
Change (1 year)
0.00%
Country
US
Trade Acorda Therapeutics, Inc. (ACOR)

Category

Number of shares outstanding for Acorda Therapeutics, Inc. (ACOR)
Number of shares outstanding as of August 2026: 0
According to Acorda Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Acorda Therapeutics, Inc. (ACOR) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors